Search Results

BioForest

Prevencio and Emory Winship Cancer Institute AI-driven HART CVE Test Data Predicts Risk of Adverse Cardiovascular Effects Associated with Prostate Cancer Therapy

Prevencio, Inc. announces the presentation of data using its Artificial Intelligence driven HART CVE blood test for prediction of subsequent adverse cardiac events in prostate cancer patients undergoing radiotherapy and androgen deprivation therapy.

February 7, 2024

·

4 min read

BioForest

Massachusetts General Hospital Researchers and Prevencio Announce AI-driven HART® CVE Blood Test Accuracy for Patients with Coronary Chronic Total Occlusion

Prevencio, Inc. announces the presentation of patient data demonstrating that its Artificial Intelligence -driven HART® CVE blood test is highly accurate for risk assessment in patients with total blockage of a heart artery, also known as coronary Chronic Total Occlusion.

October 24, 2023

·

4 min read

Business

Prevencio Announces Agreement with Alivio Health Expanding Access to AI-Driven Cardiac HART Tests Offered by Atlas Genomics

Prevencio, Inc. today announces that Atlas Genomics, Prevencio’s performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencio’s HART tests.

July 19, 2022

·

4 min read

BioForest

Prevencio Announces National Medicare Pricing for Company’s Three AI-Powered HART® Cardiac Blood Tests

Prevencio, Inc., The AI-Powered Cardiac Blood Test Company, announced the Centers for Medicare & Medicaid Services has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART® cardiac blood tests.

January 10, 2023

·

3 min read

BioForest

Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate for Predicting Major Cardiac Events in Patients with Chronic Kidney Disease

Prevencio, Inc. today announces the presentation of patient data demonstrating its Artificial Intelligence (AI)-driven HART CVE blood test is highly accurate in determining whether a person with chronic kidney disease (CKD) will have a heart attack or major adverse cardiac event within the next two years.

November 3, 2022

·

5 min read

BioForest

Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate in Patients with Diabetes for Predicting Heart Attack, Stroke, and Cardiac Death Risk

Prevencio, Inc. today announces the presentation of patient data demonstrating its Artificial Intelligence (AI)-driven HART CVE blood test is highly accurate in determining whether a person with diabetes will have a heart attack or major cardiac event within the next year.

April 12, 2022

·

5 min read

BioForest

Prevencio’s AI-driven HART CVE Blood Test Demonstrates Usefulness in Spinal Cord Injury Patients

Prevencio, Inc. today announces the presentation of data acquired in patients with spinal cord injury demonstrating that its Artificial Intelligence (AI)-driven HART CVE blood test is useful, low risk and as accurate as currently used cardiac risk imaging tests that require radiation exposure.

October 4, 2021

·

4 min read

BioForest

Prevencio’s Novel AI-Driven HART CADhs Blood Test Significantly More Accurate than Troponin for Obstructive Heart Disease

Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.

September 1, 2021

·

4 min read

BioForest

Prevencio Announces U.S. Patent Issuance for Novel, Artificial Intelligence-driven Blood Test for Cardiac Risk

Prevencio, Inc. today announces the United States Patent Office’s issuance of a patent for its highly accurate blood test, HART CVE, for a patient’s one-year risk of heart attack, stroke, or cardiovascular death.

August 4, 2021

·

4 min read

BioForest

Prevencio and Seattle Children’s Research Institute Present Highly Accurate, AI-driven HART KD Data on First Blood Test for Kawasaki Disease at Premiere International Kawasaki Disease Scientific Sessions

Prevencio, Inc. announces presentation of highly accurate data on an Artificial Intelligence -driven blood test for Kawasaki disease at the International Kawasaki Disease Scientific Sessions in Japan.

November 9, 2021

·

5 min read